A pharmaceutical company is developing a new drug for a rare autoimmune disease. Initial clinical trials show that 70% of patients experienced a significant reduction in symptoms. The company's CEO claims this success rate is highly promising for securing regulatory approval. Which of the following, if true, would most seriously challenge the CEO's claim about *securing regulatory approval*?
- AThe cost of producing the new drug is projected to be exceptionally high, limiting its market accessibility.
- BThe drug's side effects, while mild, are common and require daily management.
- CThe trial included only 20 patients, and there was no placebo control group.
- DA competing pharmaceutical company is developing a similar drug with a 75% success rate.
Show answer & explanationAnswer & explanation
Correct answer: C. The trial included only 20 patients, and there was no placebo control group.
The CEO's claim is about 'securing regulatory approval' based on a '70% success rate'. Regulatory bodies require robust evidence of a drug's efficacy and safety. Option A points to a critically flawed trial design: a small sample size (20 patients) and the absence of a placebo control group. Without a control group, it's impossible to determine if the 70% reduction is due to the drug or other factors (e.g., placebo effect, natural remission). This lack of scientific rigor would be a major hurdle for regulatory approval, seriously challenging the CEO's claim.
Why the other options are wrong
- A. High production cost affects profitability and accessibility, not the scientific basis for regulatory approval.
- B. Mild, common side effects can be a concern, but a lack of robust evidence for efficacy (due to trial design flaws) is a more fundamental challenge to *securing regulatory approval*.
- D. A competing drug might affect market share or commercial success, but doesn't directly challenge the likelihood of *this drug* securing approval based on its own merits and trial data.
Challenging Regulatory Approval Claims
To challenge a claim about securing regulatory approval, identify fundamental flaws in the data collection, trial design, or safety profile that would prevent regulators from deeming the product safe and effective.
- Regulatory approval relies on rigorous scientific evidence.
- Look for issues related to trial design (e.g., control groups, sample size, blinding).
- Safety concerns (serious side effects) are also critical factors.
Memory trick: The bridge needs solid foundations, not just paint.